# Nuclide record prrt-plus-captem (pairing). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/pairings/prrt-plus-captem/>
  a schema:MedicalTherapy ;
  nuclide:kind "pairing" ;
  schema:identifier "prrt-plus-captem" ;
  schema:name "PRRT (177Lu-DOTATATE) with capecitabine and temozolomide (CAPTEM)"@en ;
  schema:description "For some pancreatic neuroendocrine tumours, doctors add two chemotherapy tablets (capecitabine and temozolomide) to the radioactive PRRT treatment. Trial data suggest the combination may control the pancreatic tumours for longer than either treatment alone, though it caused more blood-count side effects in one gut-tumour subgroup."@en ;
  schema:url <https://nuclide.cc/pairings/prrt-plus-captem/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4122>, <https://ascopubs.org/doi/10.1200/JCO.2020.38.4_suppl.604>, <https://www.jons-online.com/special-issues-and-supplements/2020/2020-year-in-review-neuroendocrine-tumors/177lu-octreotate-prrt-temozolomide-capecitabine-in-pancreas-and-updated-midgut-nets>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9790144/> ;
  nuclide:tag "neuroendocrine tumours", "chemoradionuclide therapy" ;
  nuclide:related <https://nuclide.cc/indications/pancreatic-net/>, <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/drugs/temozolomide/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/people/jonathan-strosberg/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:pairs <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/capecitabine/> .